Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.

Oncology (Williston Park, N.Y.)

Volumn 20, Issue 14, 2006, Pages

  Shashaty, George ^a   Frankewich, Raymond ^a   Chakraborti, Tamal ^a   Choudary, Jasti ^a   Al Fayoumi, Suliman ^a   Kacuba, Alice ^a   Castillo, Sonia ^a   Robie Suh, Kathy ^a   Rieves, Dwaine ^a   Weiss, Karen ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; DEFERASIROX; DEFEROXAMINE; IRON; IRON CHELATING AGENT; SIDEROPHORE; TRIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMOSIDEROSIS; HUMAN; IRON OVERLOAD; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; BENZOIC ACIDS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; FEMALE; HEMOSIDEROSIS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; SIDEROPHORES; TRIAZOLES;

EID: 33847712566     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)